Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-04

FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for IRBESARTAN AND HYDROCHLOROTHIAZIDE from Teva Pharmaceuticals USA, Inc., indicating a labeling-related update to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IRBESARTAN AND HYDROCHLOROTHIAZIDE (irbesartan and hydrochlorothiazide)

Snippet

SUPPL AP for IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)